Type | Featured cytokines | Stimulus | Signal pathways | Role in metastasis | Target drugs/agents | Reference |
---|---|---|---|---|---|---|
MDSC | IL-6, IL-1b, GM- CSF, G-CSF, VEGF, and MCP-1 | IL-6, IL-1b, GM- CSF, G-CSF, VEGF, and MCP-1 | EZH2/NF-KB signaling, CCL26/CX3CR1, STAT3 pathway and NF-κB pathway | Promotion of immune suppression, Enhancement of angiogenesis and vascular permeability and Induction of tumor-induced immunosuppression | Sildenafil, Pexidartinib, AZD5069, Epacadostat | |
CAFs | TGF-β, HGF, PDGF, FGF-2, SDF-1, ROS | TGF-β, HGF, PDGF, FGF-2, SDF-1, ROS | IL-6/STA T3 pathway, TGF-β Signaling Pathway, Wnt/β-catenin Signaling Pathway, HGF/c-Met Signaling Pathway | Promotion of tumor growth and metastasis, Modulation of tumor microenvironment, Induction of immune evasion and Involvement in EMT process | FAP Inhibitors, Vismodegib, Galunisertib (LY2157299), Plerixafor (AMD3100) | |
Treg cells | IL-2, IL-10, TGF-β, IL-35, TNF-α and IFN-γ | interaction of TCR with IL-10 and TGF-b signaling | FoxP3 pathway, CTLA-4 pathway, IDO access, IL-2/STAT5 pathway: | Immunosuppressive, Promote immune evasion, Hyperactivity of Treg cells in tumor cell promotes tumor invasiveness and leads to a compromised T-cell immune response through Cytokines | Galunisertib (LY2157299), Ipilimumab, Epacadostat, Daclizumab, MEDI6383 | |
TAM | IL-6, VEGF, Arg1, IL-10, TGF-β, IL-4, IL-13, CSF-1, CCL2, CXCL12, CTG, IDO, CCL17, CCL18, and CCL22 | IL-4, IL-13, CSF-1, CCL2, CXCL12, and CTG | STAT3, NF-κB, TGF-β/Smad, PI3K/AKT, MAPK, HIF-1α and PD-1/PD-L1, CSF-1/CSF-1R | Promote tumor growth, promote tumor metastasis, suppress anti-tumor immune response and promote inflammation and immune regulation | Pexidartinib (PLX3397), IPI-549, Nivolumab | |
TANs | IL-8, VEGF, MMP-9, TGF-β, ROS, proteinases, IFN-γ | TGF-β | JAK/STAT, NF-κB, PI3K/AKT | Promote tumor growth, suppress immune response, direct tumor cell killing, and activate antitumor immunity | BMS-986,253, Galunisertib (LY2157299) |